Outlook Therapeutics Inc 41O
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 41O is a good fit for your portfolio.
News
-
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances
-
Outlook Therapeutics Shares Fall Premarket as Another ONS-5010 Study Needed
-
Outlook Therapeutics Shares Plumb New Depths After FDA Setback
-
Outlook Therapeutics Shares Plummet Premarket as FDA Rejects ONS-5010
-
Outlook Therapeutics' stock tumbles 71% premarket after FDA rejects treatment for wet AMD
Trading Information
- Previous Close Price
- €7.10
- Day Range
- €7.10–7.35
- 52-Week Range
- €5.50–11.31
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €169.69 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
Comparables
Valuation
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.97 | 5.84 |
Price/Sales | — | — | 20.48 |
Price/Cash Flow | — | — | 401.32 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 0.87 | 18.43 | 5.32 |
Current Ratio | 1.07 | 18.78 | 5.46 |
Interest Coverage | −71.52 | — | −22.10 |
Quick Ratio
41O
EQRX
ACLX
Profitability
|
Metric
|
41O
|
EQRX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −209.78% | −15.72% | −1.99% |
Return on Equity (Normalized) | — | −16.71% | −3.75% |
Return on Invested Capital (Normalized) | −2,826.29% | −21.31% | −7.24% |
Return on Assets
41O
EQRX
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Yycjltzsn | Vgsvbq | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qpykgbpq | Chyywz | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ntytffwj | Wrjz | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Bnrrqxm | Ydtc | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kfhchckv | Gvwn | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Chgplsfy | Cbrrs | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yyjcjcng | Ybkgjlb | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Cnxdlgk | Vwhs | $12.8 Bil | |||
| Incyte Corp
INCY
| Vwpwnpbqy | Fyxqb | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Twvrznsvt | Cwvkjrs | $12.2 Bil |